Clinical Trials Logo

Rectal Adenocarcinoma clinical trials

View clinical trials related to Rectal Adenocarcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04814784 Not yet recruiting - Clinical trials for Rectal Adenocarcinoma

Role of Neoadjuvent Radiotherapy in Locally Advanced Cancer Rectum

Start date: March 31, 2021
Phase:
Study type: Observational

This is a retrospective study comparing neoadjuvent short course radiotherapy to conventional chemoradiation in locally advanced cancer rectum and the effect of both regimens in overall survival and disease free survival

NCT ID: NCT04621370 Not yet recruiting - Rectal Cancer Clinical Trials

A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer

PRIME-RT
Start date: December 7, 2020
Phase: Phase 2
Study type: Interventional

PRIME-RT is an open label, multi-centre phase II randomised trial with 1:1 allocation between arm A and arm B. The principal research question is whether the addition of durvalumab to FOLFOX chemotherapy and radiation treatment (either SCRT or LCRT) in the neoadjuvant setting for patients with locally advanced rectal cancer (LARC) improves rates of complete response. The working hypothesis is that the use of radiation and cytotoxic chemotherapy may prime the tumour immune microenvironment for treatment with immune checkpoint blockade. The main trial will commence after completion of a safety run-in which will enrol at least three patients per arm to test the safety and tolerability of the treatment combinations in each.

NCT ID: NCT04090450 Not yet recruiting - Clinical trials for Rectal Adenocarcinoma

Optimisation of Radiotherapy in Rectal Cancer (ORREC)

ORREC
Start date: September 23, 2019
Phase:
Study type: Observational

This is a retrospective study using images acquired routinely for diagnosis of rectal cancer to see if these could be used to predict responses to radiotherapy treatment and if it can, whether the treatment can be optimised to produce better outcome for patients. Using a clinical database, patients who have had neo-adjuvant chemo-radiotherapy will be recruited, their diagnostic images and radiotherapy planning scan will be obtained. By use of imaging registration and clinical information, the question of why some patients respond well to radiotherapy and some don't could be answered.